<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138929</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0838</org_study_id>
    <secondary_id>NCI-2014-01455</secondary_id>
    <nct_id>NCT02138929</nct_id>
  </id_info>
  <brief_title>LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma</brief_title>
  <official_title>A Phase I Study of LDE225 in Combination With Everolimus in Patients With Advanced Gastroesophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest tolerable dose of LDE225 that
      can be given in combination with everolimus to patients with esophageal or GEJ cancer. The
      safety of the drug combination will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:

      If participant is found to be eligible to take part in this study, participant will be
      assigned to a combination dose level of the study drugs based on when participant joins this
      study. Up to 6 participants will be enrolled at each dose level. The first group of
      participants will receive the lowest dose level of LDE225. Each new group will receive a
      higher dose than the group before it, if no intolerable side effects were seen. All
      participants will receive the same dose level of everolimus. This will continue until the
      highest tolerable combination dose of LDE225 and everolimus is found. Up to 24 participants
      will be enrolled in this part of the study.

      Once the highest tolerable dose of the combination of LDE225 and everolimus is found, up to
      18 participants will receive the combination dose level that was found to be well tolerated
      in the earlier part of the study.

      Study Drug Administration:

      Every study cycle is 28 days.

      Participant will take up to 4 capsules or tablets of LDE225 by mouth 1 time every day.
      Participant's doctor will tell participant how many capsules/tablets participant will need to
      take. Participant should take the study drug each time with a glass of water (about 8 ounces
      total) at the same time every day. Participant should swallow the study drug whole, one
      capsule/tablet every 2 minutes, without chewing or opening the study drug. Participant should
      eat a light breakfast (such as toast and jam) at least 2 hours before taking the study drug,
      then participant should not eat or drink anything for at least 1 hour after the dose.

      Participant will take up to 2 tablets of everolimus by mouth 1 time every day with the LDE225
      capsules without food. Participant will take the tablets each time with a glass of water at
      the same time every day. The tablets should be swallowed whole and not chewed or crushed.

      If participant cannot swallow the everolimus tablets, the tablets should be dissolved in
      water just before taking them. Add about 2 tablespoons of water into a glass. The tablets
      should then be added and stirred gently until the tablets are dissolved. This mixture should
      then be drunk. Afterwards, the glass should be rinsed with an additional 2 tablespoons of
      water and drunk. Participant's doctor will discuss this with participant.

      If participant vomits after taking participant's dose of study drugs, participant should not
      take another dose that day.

      It is very important that participant takes the study drugs given to participant just as the
      study doctor tells participant and that participant does not miss any dose. If participant
      forgets to take a dose of LDE225, participant should take it as soon as participant remembers
      (within 6 hours of the missed dose). If more than 6 hours have passed, participant should
      skip that dose and take participant's next dose the next day as planned. If participant
      forgets to take a dose of everolimus, participant should skip that dose and take
      participant's next dose the next day as planned.

      If participant has a study visit that day, participant should take participant's dose of
      study drugs at the clinic.

      Participant will need to store LDE225 in participant's refrigerator at all times. Everolimus
      can be stored at room temperature. Participant should not share participant's supply of
      LDE225 and everolimus with anyone. Participant will keep a study drug diary to help
      participant keep track of participant's study drug doses. If participant misses or delays a
      dose, participant should write it down in the diary. Participant should bring the diary to
      every study visit.

      At the end of each cycle and when participant stops taking part in the study, participant
      will return any leftover study drugs to the study nurse.

      Study Visits:

      On Day 1 of every cycle:

        -  Participant will have a physical exam.

        -  Blood (about 2 teaspoons) will be drawn for routine tests.

        -  If participant can become pregnant, blood (about 1 teaspoon) or urine will be collected
           for a pregnancy test.

      Every week during Cycle 1 only, the study staff will call and ask participant how participant
      is doing.

      On Day 1 of Cycle 2 and every 2 cycles after that, participant will have an EKG.

      On Day 1 of Cycle 3 and every 2 cycles after that, participant will have a CT scan or MRI of
      the chest, abdomen, and pelvis to check the status of the disease.

      If the doctor thinks it is needed, extra blood may be drawn to follow up on any side effects.

      Length of Study:

      Participant may continue taking the study drugs for as long as the doctor thinks it is in
      participant's best interest. Participant will no longer be able to take the study drugs if
      the disease gets worse, if intolerable side effects occur, or if participant is unable to
      follow study directions.

      Participation on the study will be over after the follow-up visit (described below).

      End-of-Study Visit:

      Within 14 days after participant's last dose of study drugs:

        -  Participant will have a physical exam.

        -  Blood (about 2 tablespoons) will be drawn for routine tests, to check the cholesterol
           levels in participant's blood, and to check how well participant's blood clots.
           Participant will need to fast for at least 8 hours before this blood draw.

        -  Participant will have an EKG.

        -  Participant will have a CT scan or MRI of the chest, abdomen, and pelvis to check the
           status of the disease, if the doctor thinks it is needed.

        -  If participant can become pregnant, blood (about 1 teaspoon) or urine will be collected
           for a pregnancy test.

      Follow-Up Visit:

      At 30 days after the end-of-study visit:

        -  Participant will have a physical exam.

        -  Blood (about 2 tablespoons) will be drawn for routine tests.

        -  Participant will have an EKG.

        -  If participant can become pregnant, blood (about 1 teaspoon) or urine will be collected
           for a pregnancy test.

      About 3 months after the follow-up visit, participant will be contacted by the study staff by
      telephone and/or seen in the clinic. Participant will be asked about any drugs participant
      may be taking and about participant's general health. If participant is called, the call will
      take about 5-10 minutes.

      This is an investigational study. LDE225 is not FDA approved or commercially available.
      Everolimus is FDA approved and commercially available to treat kidney, breast, and pancreatic
      cancers. The combination of LDE225 and everolimus to treat esophageal or GEJ cancer is
      investigational.

      The study doctor can explain how the study drugs are designed to work.

      Up to 42 participants will be enrolled in this study. All will take part at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 10, 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of LDE225 in Combination with Everolimus in Participants with Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction (GEJ) or Stomach in the Second or Third Line Setting</measure>
    <time_frame>10 weeks</time_frame>
    <description>Maximum tolerated dose (MTD) defined as highest dose level for the combination therapy with no more than 1 out of 6 patients experiencing dose limiting toxicity (DLT). DLT defined as an adverse event (AE) or abnormal laboratory value assessed as at least possibly related to the study medication, occurs â‰¤56 days following the first dose of LDE225 (DLT assessment period).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of LDE225 in Combination with Everolimus in a Cohort of Participants with Metastatic Nuclear Gli-1 Expressing Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach per CTCAE.</measure>
    <time_frame>30 days after last dose of study drug given.</time_frame>
    <description>A Bayesian method by Thall, Simon, and Estey [37] used for safety monitoring, starting from the 5th patient. The monitoring rule for toxicity is Pr (P(Tox) &gt; 0.25 | data) &gt; 0.80, where P(Tox) is the proportion of patients that experience DLT and it has a prior distribution of beta (0.5, 1.5).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus + LDE 225</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Everolimus at a dose of 10 mg by mouth daily with dose escalation of LDE 225 from 200 mg - 800mg by mouth daily. Study cycle is 28 days.
Dose Expansion: Everolimus at a dose of 10 mg by mouth daily. LDE 225 at MTD from Dose Escalation. Study cycle is 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.</description>
    <arm_group_label>Everolimus + LDE 225</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>Zortress</other_name>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE 225</intervention_name>
    <description>Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.
Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase.</description>
    <arm_group_label>Everolimus + LDE 225</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically or cytologically confirmed adenocarcinoma of
             esophagus,gastroesophageal junction, or stomach which is Gli-1 positive (labeling
             index [LI] greater than or equal to 5%). Testing is to be performed in a CLIA
             certified laboratory. The patients must have an archival tumor sample to facilitate
             this testing.

          2. Patients must have an unresectable locally advanced or metastatic adenocarcinoma.

          3. Patients agreeing to the optional biomarker study in the expansion phase only need to
             have an accessible primary tumor. (Optional biomarker studies will be done in up to 18
             patients in the expansion phase only.)

          4. Patient must have received at least one, and no more than two prior systemic therapies
             for metastatic cancer.

          5. Patients whose esophageal or GEJ cancer has become metastatic or unresectable locally
             advanced within 6 months of completing definitive therapy for localized or locally
             advanced cancer can be considered as having received one line of therapy for advanced
             cancer.

          6. Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as greater than 20 mm with
             conventional techniques or as greater than 10 mm with spiral CT scan.

          7. Male or female patients greater than or equal to 18 years old.

          8. ECOG performance status less than 2.

          9. Patients must have normal organ and marrow function as defined below: leukocytes
             greater than 3,000/mcL; absolute neutrophil count greater than1,500/mcL; platelets
             greater than 100,000/mcL; Hemoglobin (Hgb) greater than or equal to 9 g/dL
             (transfusions are allowed); total bilirubin within normal institutional limits;
             AST(SGOT)/ALT(SGPT) less than 2.5 x institutional upper limit of normal (ULN) or less
             than or equal to 5 x institutional ULN if liver metastasis are present; Serum
             creatinine less than or equal to 1.5 x ULN or 24-hour clearance greater than or equal
             to 50ml/min; Plasma creatine phosphokinase (CK) less than 1.5 x ULN; INR less than or
             equal to 2; Fasting serum cholesterol less than or equal to 300 mg/dL OR less than or
             equal to 7.75 mmol/L AND fasting triglycerides less than or equal to 2.5 x ULN.

         10. Patient should be able to swallow and retain oral medications.

         11. Women of childbearing potential and men must use two forms of contraception
             (non-hormonal or barrier method of birth control; abstinence) prior to study entry and
             for the duration of study participation and for 6 months after the final dose of study
             treatment.

         12. Ability to understand and the willingness to sign a written informed consent document.
             Signed informed consent will be obtained prior to any screening procedures.

        Exclusion Criteria:

          1. Patients currently receiving anticancer therapies or who have received anticancer
             therapies within 4 weeks of the start of Everolimus and LDE225 (including
             chemotherapy, radiation therapy, antibody based therapy, etc.).

          2. Uncontrolled diabetes mellitus as defined by HbA1c greater than 8% despite adequate
             therapy. Patients with a known history of impaired fasting glucose or diabetes
             mellitus (DM) may be included, however blood glucose and antidiabetic treatment must
             be monitored closely throughout the trial and adjusted as necessary.

          3. Patients who have any severe and/or uncontrolled medical conditions such as: a)
             unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction
             less than or equal to 6 months prior to start of Everolimus, serious uncontrolled
             cardiac arrhythmia, or any other clinically significant cardiac disease; b)
             symptomatic congestive heart failure of New York Heart Association Class III or IV; c)
             active (acute or chronic) or uncontrolled severe infection, liver disease such as
             cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable
             HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA); d) known severely impaired lung
             function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at
             rest on room air); e) active, bleeding diathesis.

          4. Patients who have a history of another primary malignancy, with the exceptions of:
             non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from
             which the patient has been disease free for greater than or equal to 3 years.

          5. Patients with a history of non-compliance to medical regimens or who are considered
             potentially unreliable or will not be able to complete the entire study.

          6. Pregnant or nursing (lactating) women.

          7. Women of child-bearing potential (WOCBP), defined as all women physiologically capable
             of becoming pregnant, must use highly effective methods of contraception during the
             study and 6 months after. Hormonal contraception methods (e.g. oral, injected,
             implanted) are not allowed as it cannot be ruled out that the study drug decreases the
             effectiveness of hormonal contraception. Highly effective contraception methods
             include combination of any two of the following: a) Placement of a non-hormonal
             intrauterine device (IUD) or non-hormonal intrauterine system (IUS); b) Barrier
             methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps)
             with spermicidal foam/gel/film/cream/ vaginal suppository; c. Total abstinence (When
             this is in line with the preferred and usual lifestyle of the patient. Periodic
             abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and
             withdrawal are not acceptable methods of contraception.);

          8. (Continued from # 7): or d) Male/female sterilization. (Sterilization: Patient has had
             surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at
             least six weeks before taking study treatment. In case of oophorectomy alone, only
             when the reproductive status of the woman has been confirmed by follow up hormone
             level assessment. Male partner sterilization (with the appropriate post-vasectomy
             documentation of the absence of sperm in the ejaculate). [For female study patients,
             the vasectomized male partner should be the sole partner for that patient.]).

          9. (Continued from # 8): Women are considered post-menopausal and not of child-bearing
             potential if they have had 12 months of natural (spontaneous) amenorrhea with an
             appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or
             have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal
             ligation at least six weeks prior to randomization. In the case of oophorectomy alone,
             only when the reproductive status of the woman has been confirmed by follow up hormone
             level assessment is she considered not of child-bearing potential.

         10. Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate
             contraception, during the study and for 6 months after the end of treatment (Male
             patients must use highly effective (double barrier) methods of contraception (e.g.,
             spermicidal gel plus condom) for the entire duration of the study, and continuing
             using contraception and refrain from fathering a child for 6 months following the
             study drug. A condom is required to be used also by vasectomized men as well as during
             intercourse with a male partner in order to prevent delivery of the study treatment
             via seminal fluid.).

         11. Patients with known brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events.

         12. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to LDE 225 or Everolimus in the study or other rapamycin analogs (e.g.
             sirolimus, temsirolimus).

         13. Patients who are receiving treatment with medications known to be moderate and strong
             inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have
             narrow therapeutic index, and that cannot be discontinued before starting treatment
             with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued at
             least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting
             treatment with LDE225.

         14. Patients receiving any medications or substances that are inhibitors or inducers of
             CYP 450 3A4 are ineligible.

         15. Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular
             dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on
             concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as
             HMG CoA inhibitors (statins), clofibrate and gemfibrozil, and that cannot be
             discontinued at least 2 weeks prior to starting LDE225 treatment. Patients who are
             planning on embarking on a new strenuous exercise regimen after initiation of study
             treatment, should also be excluded. Muscular activities, such as strenuous exercise,
             that can result in significant increases in plasma CK levels should be avoided whilst
             on LDE225 treatment.

         16. Concurrent medical condition requiring the use of immunosuppressive medications or
             immunosuppressive doses of systemic or absorbable topical corticosteroids (doses
             greater than 10mg/day prednisone or equivalent). Inhaled or intranasal corticosteroids
             (with minimal systemic absorption) may be continued. Non-absorbed intra-articular
             steroid injections are allowed. The exception to the use of steroids is the treatment
             of serious adverse events (SAEs) such as pneumonitis and the prevention of emesis.

         17. Known history of HIV seropositivity.

         18. Patients who have received live attenuated vaccines within 1 week of start of
             Everolimus and during the study.

         19. Impaired cardiac function or clinically significant heart disease, including any one
             of the following: a) Angina pectoris within 3 months; b) Acute myocardial infarction
             within 3 months; c) QTcF greater than 450 msec for males and greater than 470 msec for
             females on the screening electrocardiogram (ECG); d) A past medical history of
             clinically significant ECG abnormalities or a family history of prolonged QT-interval
             syndrome; e) Other clinically significant heart disease (e.g. congestive heart
             failure, uncontrolled hypertension, history of labile hypertension, or history of poor
             compliance with an antihypertensive regimen).

         20. All patients known to be positive for hepatitis B will be excluded from the study, and
             those at high risk for hepatitis B infection will be screened.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaffer Ajani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Advanced adenocarcinoma of the esophagus</keyword>
  <keyword>Advanced adenocarcinoma of the gastroesophageal junction</keyword>
  <keyword>GEJ</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Afinitor</keyword>
  <keyword>Zortress</keyword>
  <keyword>RAD001</keyword>
  <keyword>LDE 225</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

